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Abstract
Drug repurposing ofers advantages over traditional drug development in terms of cost, speed and improved patient outcomes. 
The receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) inhibitor denosumab is approved for the preven-
tion of skeletal-related events in patients with advanced malignancies involving bone, including solid tumours and multiple 
myeloma. Following improved understanding of the role of RANK/RANKL in cancer biology, denosumab has already been 
repurposed as a treatment for giant cell tumour of bone. Here, we review the role of RANK/RANKL in tumourigenesis, 
including efects on tumour initiation, progression and metastasis and consider the impact of RANK/RANKL on tumour 
immunology and immune evasion. Finally, we look briely at ongoing trials and future opportunities for therapeutic synergy 
when combining denosumab with anti-cancer agents such as immune checkpoint inhibitors.
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Drug repurposing as a therapeutic strategy 
in cancer
Drug discovery and development requires many years of 
research and financial investment [1]. Repurposing an 
approved therapeutic agent is generally faster and more cost 
efective than novel drug development because the largest 
and most ineicient part of the development process has 
been bypassed [1]. Repurposing may take 3–12 years, com-
pared with up to 17 years to develop a new drug, and repur-
posed drugs have the beneit of established safety proiles, 
which contribute to lower implementation failure rates than 
seen with novel agents [1]. Drugs with a history of safe use 
and a favourable toxicology proile may be candidates for 
repurposing if they have both a plausible mechanism of 
action and evidence of eicacy in the new indication [1]. 
Drug repurposing is one of the oldest development path-
ways for anti-cancer medicines; for example, anthracyclines, 
which are used extensively in the management of breast 
cancer and lymphoma, were tested as antibiotics but proved 
to be too toxic [2]. Thalidomide is another example of a 
drug successfully repurposed as a cancer treatment. Used to 
alleviate morning sickness in pregnant women, thalidomide 
was withdrawn after causing severe teratogenicity, but later 
demonstrated response rates of 25–35% in relapsed/refrac-
tory multiple myeloma and was subsequently approved for 
treatment of this cancer [3]. This inding prompted develop-
ment of thalidomide analogues, such as lenalidomide and 
pomalidomide, which are now typically preferred in clinical 
practice over the original agent [3].
Recently, there has been renewed interest in repurposing 
in the oncology ield: drugs approved in other indications 
have been shown to induce cancer cell death, suppress 
aspects of cancer cell behaviour, or even prevent cancer 
development. Examples of repurposed drugs that have 
shown anti-cancer activity in at least one clinical trial 
include cimetidine, clarithromycin, verapamil and pravas-
tatin [3]. Aspirin is also a potential candidate for repurpos-
ing as an anti-cancer agent. There is some evidence, from 
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clinical trials investigating prevention of cardiovascular 
disease and from observational studies, that it may reduce 
cancer incidence or death [4]. Similar indings have emerged 
from interventional studies evaluating the efect of aspirin 
on mortality and disease recurrence in cancer patients [4]. 
Potential antineoplastic properties of the oral antidiabetic 
agent metformin are also being investigated following obser-
vations that it reduced cancer incidence by 37% in patients 
with diabetes [5].
A further avenue open to exploration is repurposing drugs 
that target the receptor activator of nuclear factor kappa-
B (RANK) ligand (RANKL) signalling system [6], which 
has an established role in regulating bone remodelling [7, 
8]. The RANKL inhibitor denosumab was irst approved in 
2010 and is now indicated for the prevention of skeletal-
related events (SREs) in adults with advanced malignancies 
involving bone [9]. The denosumab label has recently been 
expanded to include the prevention of SREs in patients with 
multiple myeloma [9, 10]. Observations that some stromal 
cells in giant cell tumour of bone (GCTB) express RANKL, 
possibly leading to the recruitment of RANK-expressing 
osteoclast-like giant cells, led to increased understanding 
of the role of RANK–RANKL signalling in the aetiology of 
GCTB and then to investigations of the therapeutic poten-
tial of denosumab in patients with GCTB [11, 12]. Posi-
tive clinical trial results led to the approval of denosumab 
in 2013 for use in adults and skeletally mature adolescents 
with GCTB that is unresectable or where surgical resec-
tion may result in severe morbidity [13]. Accumulating data 
on the RANK–RANKL pathway raise the possibility that 
denosumab could be repurposed for use in other types of 
cancer. Evidence suggests that RANK–RANKL signalling 
may have osteoclast-independent efects on tumour biology, 
with RANK/RANKL activity demonstrating a positive cor-
relation with tumour progression and advanced disease [14]. 
Moreover, trials including denosumab have demonstrated 
positive efects on survival outcomes in patients with can-
cer, including increased overall survival (OS) in lung cancer 
and increased disease-free survival in non-metastatic breast 
cancer [15, 16]. Recent data also suggest that denosumab 
and immune checkpoint inhibitors may act synergistically 
to provide additional beneit [17]. This review explores the 
RANK–RANKL axis in cancer biology and the potential for 
repurposing denosumab.
The RANK–RANKL axis: more than bone 
turnover
RANKL, its transmembrane signalling receptor RANK, 
and the decoy receptor osteoprotegerin (OPG) belong to 
the tumour necrosis factor superfamily [7]. Competition 
between OPG and RANK to bind RANKL regulates RANK 
activation and, therefore, its signalling function [7]. Binding 
of RANKL to RANK initiates various signal-transduction 
pathways, including production of nuclear factor kappa B 
[7], the eponymous member of a transcription factor fam-
ily implicated in cancer development and progression, in 
inlammation and in crosstalk between these two processes 
[18, 19]. While the RANK/RANKL/OPG system regulates 
osteoclast function and bone remodelling in bone homeo-
stasis [7, 8], it also has roles in immunity and development 
(Fig. 1a–c). Speciically, RANK–RANKL signalling sits at 
the interface between bone and the immune system, inlu-
encing the pathology of diseases such as rheumatoid arthri-
tis [20] and immune functions unrelated to bone including 
involvement in dendritic cell survival and function, M1 
macrophage activation and T-cell diferentiation and acti-
vation [14, 21, 22]. Additionally, RANK–RANKL signalling 
functions in epithelial growth and diferentiation, includ-
ing mammary physiology [7, 23], in lymph node develop-
ment [21], in skeletal muscle [24] and in the central nervous 
system (CNS) [8]. For example, RANK–RANKL signal-
ling has been implicated in the formation and function of 
hair follicles, intestinal microfold cells, thymic medullary 
epithelium and mammary glands [7, 25]. RANK protein 
is also expressed in bronchial (but not alveolar) epithelial 
cells [23]. Of note, in mammary gland diferentiation and 
the development of the lobuloalveolar breast tissue architec-
ture required for lactation [26], RANK–RANKL signalling 
promotes the proliferation and survival of mammary epithe-
lial cells [26] and constitutive signalling may promote the 
propagation of RANK-expressing stem cells at the expense 
of normal diferentiation [27]. RANKL expression is driven 
by progesterone-responsive cells in the breast and is required 
for progesterone-driven epithelial proliferation [28, 29]. In 
skeletal muscle, the RANK–RANKL axis has been impli-
cated in the regulation of calcium storage, inluencing den-
ervated muscle function [24]. Furthermore, in the CNS, the 
RANK–RANKL axis plays a role in thermoregulation [8]. 
RANK, RANKL and OPG are, therefore, expressed across 
a variety of tissue types (Fig. 2a–c). Notably, RANK and 
OPG have relatively broad expression in normal tissues, 
while RANKL is largely restricted to osteoblasts and hae-
matopoietic lineages (Fig. 2a), where it is expressed in 
T lymphocytes and basophils [30–32].
The RANK–RANKL axis in cancer biology
Given its varied roles in human physiology, interest has 
increased in the role of the RANK–RANKL axis in tumouri-
genesis, speciically in its functions beyond bone metabo-
lism. Cells from various tumour types express RANK, 
RANKL and OPG (Fig. 3a–c) and RANK–RANKL signal-
ling appears to be involved in tumour initiation, progression 
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and metastasis (Fig. 1d) [6, 7, 25, 33]. With regard to bone 
metastasis, the efects of RANK/RANKL seem likely to be 
indirect, mediated by an osteoclast-dependent mechanism, 
or direct, via interaction of RANKL with RANK-expressing 
cells [6, 7, 25, 33]. However, there is evidence for involve-
ment of the RANK/RANKL/OPG system in the develop-
ment and metastasis of melanoma, breast, hepatocellular, 
lung, prostate and renal cell carcinomas, as well as in pri-
mary malignant tumours of the bone (osteosarcoma, multi-
ple myeloma and GCTB) [6, 7, 25, 33]. The relative levels of 
RANK/RANKL/OPG expression may inluence prognosis in 
numerous cancer types including breast, lung, endometrial, 
renal cell and gastric cancers, osteosarcoma and multiple 
myeloma (Fig. 4a, b) [34–41]. In breast cancer, microar-
ray analysis demonstrated that low RANK and high OPG 
expression were associated with longer OS (p = 0.0078 and 
p = 0.034, respectively) and disease-free survival (p = 0.059 
and p = 0.040, respectively) [34]. Immunohistochemical 
analysis demonstrated an association between high RANK 
expression and bone metastasis (p = 0.023) and shorter 
survival without bone involvement (p = 0.037) [34]. In 
another study, low RANKL expression has been associ-
ated with increased risk for bone metastases (p = 0.018) and 
shorter disease-free survival (p = 0.018) in breast cancer 
[40]. In metastatic clear cell renal cell carcinoma, an ele-
vated RANK/OPG ratio has been associated with a shorter 
median time to metastasis (p = 0.014), progression-free sur-
vival (PFS) (p = 0.001) and OS (p = 0.0001) [35]. Moreover, 
RANK expression in clear cell renal cell carcinoma has been 
identiied as an independent negative prognostic factor for 
both cancer-speciic survival and recurrence-free survival 
(p < 0.001) [42]. Additionally, high RANK expression has 
been linked to a shorter PFS (p = 0.01) and OS (p = 0.02) 
in endometrial cancer [36]. RANK-positive osteosarcomas 
Fig. 1  Involvement of the 
RANK–RANKL axis in bone 
remodelling, development, 
immunity and cancer. a In the 
mammary gland, following the 
binding of progesterone to its 
receptor, RANKL is produced. 
Increased RANKL stimulates 
mammary gland epithelial cell 
expansion via paracrine signal-
ling, leading to lactation compe-
tence. Image modiied from [96] 
under the Creative Commons 
Attribution License (https ://
creat iveco mmons .org/licen 
ses/by-nc-sa/3.0/). b Activated 
T cells and NK cells express 
RANKL, which stimulates vari-
ous processes via monocytes, 
macrophages and dendritic 
cells including dendritic cell 
survival and maturation, 
T-cell activation and NK cell 
inhibition. c Increased levels of 
RANKL have been associated 
with increased tumour growth, 
stemness, EMT and metastases. 
Throughout these processes, 
RANKL acts as a chemoat-
tractant for RANK-expressing 
cancer. d Increased RANKL 
produced by bone stromal cells, 
including cells of the osteoblast 
lineage, leads to an increased 
rate of bone remodelling [96]. 
EMT epithelial–mesenchymal 
transition, NK natural killer, PR 
progesterone, RANK receptor 
activator of nuclear factor kappa 
B, RANKL receptor activator of 
nuclear factor kappa B ligand
980 Clinical and Translational Oncology (2019) 21:977–991
1 3
are also associated with higher mortality than RANK-
negative cases (p < 0.05) [41]. A high RANKL expression 
has been associated with higher stage disease (p = 0.035) 
and a shorter OS (p = 0.008) in gastric cancer [37]. In lung 
adenocarcinoma, both high RANK (p = 0.01) and RANKL 
(p = 0.02) expression have been linked to worse OS [38]. 
Furthermore, in multiple myeloma, the serum RANKL/OPG 
ratio was found to correlate with the extent of bone disease 
(p = 0.023), and a high RANKL/OPG ratio was associated 
with an increased risk of death (p < 0.001) [39]. Such corre-
lation data should be interpreted with caution as the methods 
used to evaluate expression levels vary across studies, can 
include non-validated assays and require expertise to assess 
the results; therefore, further research is required to conirm 
these indings.
Indirect efects of RANK–RANKL signalling 
on tumour initiation, progression and metastasis: 
preclinical evidence
RANKL is well known to be involved in a cycle of oste-
oclast-mediated bone destruction and tumour activity that 
facilitates bone metastasis [7, 8, 25]. Both tumour cells 
and tumour-derived factors are involved in the production 
of RANKL and increase the RANKL/OPG ratio. Increased 
RANKL in the bone microenvironment upregulates oste-
oclastogenesis and the activation of mature osteoclasts 
(bone-resident macrophages), resulting in increased bone 
resorption. The subsequent release of growth factors and cal-
cium into the bone microenvironment stimulates additional 
proliferation of tumour cells and release of tumour-derived 
Fig. 2  a RANK, RANKL and 
OPG tissue expression. Data 
from the Human Protein Atlas 
available at www.prote inatl 
as.org [97]. RANK expres-
sion is relatively ubiquitous, 
while RANKL expression is 
efectively restricted to haema-
topoietic cells. OPG expression 
is highest in mucosal epithelial 
tissues, consistent with its 
role in modulating immune 
responses. b RANKL positive 
immune cells within a lymph 
node. Image reproduced from 
the Human Protein Atlas [97] 
under the Creative Commons 
Attribution License (https ://
creat iveco mmons .org/licen ses/
by-sa/3.0/); available at https ://
www.prote inatl as.org/ENSG0 
00001 20659 -TNFSF 11/tissu e/
lymph +node#img. c RANKL 
expression in normal breast 
tissue. Image reproduced 
from [98] under the Creative 
Commons Attribution License 
(http://creat iveco mmons 
.org/licen ses/by/4.0). OPG 
osteoprotegerin, RANK receptor 
activator of nuclear factor kappa 
B, RANKL receptor activator of 
nuclear factor kappa B ligand, 
TPM, transcripts per million
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factors, and thus further increases the RANKL/OPG ratio, 
thereby promoting continued RANKL-dependent osteoclast-
mediated bone destruction [43, 44].
With respect to bone metastasis, preclinical evidence has 
shown that high RANK expression in breast cancer cells 
increases their ability to metastasise to bone [45]. RANKL 
inhibition promoted tumour apoptosis in a mouse model of 
bone metastasis from prostate cancer, and in combination 
with docetaxel, was synergistic in improving survival [46]. 
Moreover, preclinical data have indicated that the combina-
tion of anti-RANKL therapies and AT-406 (an antagonist 
of inhibitor of apoptosis proteins) may have a beneicial 
efect on bone metastases [47]. RANKL inhibition also sup-
pressed bone invasion in mouse models of oral squamous 
cell carcinoma [48]. Furthermore, it has been shown that 
an elevated RANKL/OPG ratio increases the potential of 
human non-small cell lung cancer (NSCLC) to metasta-
sise to bone [49]. In mouse models of multiple myeloma, 
RANKL has been shown to promote the release of myeloma 
cells from dormancy through osteoclast-mediated remod-
elling of the endosteal niche, thus promoting disease pro-
gression or relapse. In line with these observations, bone 
resorption has been linked to tumour burden in patients with 
multiple myeloma [50].
In addition to these well-known bone-related pathways, 
RANK–RANKL signalling may play a role at several other 
stages of cancer development, progression and metasta-
sis [7, 25, 33]. RANKL may inluence carcinogenesis and 
Fig. 3  a Expression of RANK, RANKL and OPG in cells from 
various solid organ and haematological cancers. The results shown 
here are based upon data generated by the TCGA Research Net-
work (http://cance rgeno me.nih.gov/) obtained using the cBioPor-
tal for Cancer Genomic [95]. b RANKL expression in lung adeno-
carcinoma. c RANKL expression in pancreatic adenocarcinoma. 
Reproduced from the Human Protein Atlas [97] under the Creative 
Commons Attribution License (https ://creat iveco mmons .org/licen 
ses/by-sa/3.0/); image in b is available at https ://www.prote inatl 
as.org/ENSG0 00001 20659 -TNFSF 11/patho logy/tissu e/lung+cance 
r#img and image in c is available at https ://www.prote inatl as.org/
ENSG0 00001 20659 -TNFSF 11/patho logy/tissu e/pancr eatic +cance 
r#img. ACC adenoid cystic carcinoma, AML acute myeloid leukae-
mia, ccRCC clear cell renal cell carcinoma, chRCC chromophobe 
renal cell carcinoma, CS carcinosarcoma, DLBCL difuse large B-cell 
lymphoma, GBM glioblastoma multiforme, OPG osteoprotegerin, 
PCPG pheochromocytoma and paraganglioma, pRCC papillary renal 
cell carcinoma, RANK receptor activator of nuclear factor kappa B, 
RANKL receptor activator of nuclear factor kappa B ligand
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Fig. 4  a Association of RANK, RANKL and OPG expression with 
survival across diferent cancer types according to published studies. 
Each line represents diferent expression data as labelled; all compari-
sons are high vs low expression except for the breast cancer results, 
which are low vs high. b Association of RANK, RANKL and OPG 
expression (low or high) with 5-year overall survival rates across var-
ious solid organ and haematological cancers. OPG expression is sig-
niicantly (p < 0.001) associated with survival in urothelial, renal and 
cervical cancers, but extreme gene expression for OPG, RANKL and 
RANK also show hypothesis-generating associations in other can-
cers. Log rank p values for Kaplan–Meier plots showing results from 
analysis of correlation between mRNA expression levels and patient 
survival from TCGA datasets are plotted. Data extracted from the 
Human Protein Atlas available at www.prote inatl as.org [97]. aTCGA 
dataset. bLung-1 dataset. + Indicates a better prognosis with high gene 
expression. − Indicates a worse prognosis with high gene expression. 
CI conidence interval, HR hazard ratio, mRNA messenger RNA, 
NR not reported, OPG osteoprotegerin, RANK receptor activator of 
nuclear factor kappa B, RANKL receptor activator of nuclear factor 
kappa B ligand, RCC renal cell carcinoma
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metastatic progression through efects on RANK-express-
ing tumour cells or cells from stem/progenitor compart-
ments that express RANK [7, 25, 33]. Efects on tumour 
initiation may difer between cancer types and there has 
been particular interest in the role that RANKL may play 
in breast cancer given its physiological roles in mammary 
gland epithelia and the stem cell compartment [7, 25, 33]. 
Preclinical evidence suggests that RANK/RANKL mediate 
the pro-tumourigenic role of progesterone in the mammary 
gland [28, 29, 51]. In a mouse mammary tumour virus 
model, RANK overexpression promoted tumourigenesis in 
breast tissue after treatment with carcinogen and proges-
terone, and RANKL inhibition attenuated tumourigenesis 
in this and a spontaneous breast tumour model [51]. In 
another mouse model with breast tissue deleted for RANK, 
tumourigenesis, tumour growth and stem cell expansion 
driven by medroxyprogesterone acetate were also attenu-
ated [52]. Furthermore, mammary carcinogenesis driven 
by BRCA1 mutations relies on autocrine or paracrine 
RANK–RANKL signalling in mammary progenitor cells 
[29]. Targeting the RANK–RANKL axis could conceiv-
ably, therefore, be beneicial in patients with BRCA1 muta-
tion-positive breast cancer and may provide a rationale for 
designing clinical trials of cancer prevention [29].
Preclinical data have demonstrated that when expressed 
in lung epithelial cells or other cells of the tumour micro-
environment, RANK may also promote lung cancer devel-
opment. Signalling via RANK promoted expansion of 
cancer stem-like cells in a mechanism dependent upon 
mitochondrial respiration [23]. Female sex hormones are 
also able to promote lung cancer progression through the 
RANK–RANKL axis [23]. It has been hypothesised that 
the inluence of sex hormones on RANK/RANKL might in 
part explain gender-speciic diferences observed in epide-
miological studies of human lung cancer [23, 53]. RANKL 
expression has been associated with decreased survival in 
lung adenocarcinoma [23, 38], and RANKL inhibition has 
reduced tumour progression in mouse models of lung adeno-
carcinoma [38].
The leucine-rich repeat-containing G-protein-coupled 
receptor 4 (LGR4) has recently been identiied as a RANKL 
receptor, has been shown to have an antagonistic efect on 
osteoclast diferentiation and to promote the proliferation of 
tumour cells when overexpressed [6]. Additionally, LGR4 
expression has been associated with a poor prognosis and 
metastasis in breast, prostate and colorectal cancer [54–56]; 
however, LGR4 has been associated with improved survival 
in lung adenocarcinoma [23]. In multiple myeloma, LGR4 
has been implicated in promoting Wnt/β-catenin signalling, 
which drives proliferation [57]. It could be speculated that 
patients with tumours expressing high levels of both LGR4 
and RANKL might benefit from disruption of RANKL 
signalling.
Many of the mechanisms underlying the pro-metastatic 
activities of RANKL, including increased proliferation, 
migration and invasion of RANK-expressing tumour cells, 
could be relevant to numerous cancer types [7, 14, 25, 33]. 
RANK overexpression induced transformation and stemness 
in untransformed mammary epithelial cells, induced mark-
ers of epithelial–mesenchymal transition (EMT), known to 
be important in acquiring these metastatic capabilities [58] 
and increased invasiveness, migration and anchorage-inde-
pendent growth [59]. Additionally, RANK overexpression 
induced tumourigenesis and promoted metastasis of BRCA1-
deicient cells in immunodeicient mice [59]. Furthermore, 
disruption of RANK–RANKL signalling in mouse models 
of breast cancer reduced metastasis of RANK-expressing 
breast cancer cells to lung [7, 60] and of RANK-express-
ing melanoma cells to bone [61]; conversely, exogenous 
RANKL promoted lung metastases in mice with RANK-
expressing breast tumours [60]. In humans, high RANK/
RANKL messenger RNA expression has been signiicantly 
associated with metastatic breast adenocarcinomas [59], 
while RANKL induced markers of EMT in prostate cancer 
[62] and in head and neck squamous carcinoma cells [63]. 
RANKL has also been implicated both in the induction of 
angiogenesis and in increasing vascular permeability via 
RANK-expressing endothelial cells, which may impact intra/
extravasation and metastasis [25, 64]. Vascular endothelial 
growth factor, which is commonly expressed by tumour 
cells, enhances endothelial cell responses to RANKL [25].
Potential immunomodulatory role of RANK–RANKL 
signalling
Immune cells may represent a subset of RANKL-expressing 
cells that mediate direct efects of RANK–RANKL signal-
ling in cancer [7, 14, 25]. Such cells are commonly found 
in the tumour microenvironment but their precise roles are 
varied and not fully understood [7, 14]. The complex role 
of RANK–RANKL signalling is evident from the fact that 
it has been implicated in both the generation and regulation 
of immune responses, suggesting that RANK–RANKL sig-
nalling can enhance and suppress immunity and may afect 
inlammation, T-cell activation and immune evasion [7, 14, 
22]. Speciically, RANK–RANKL signalling supports den-
dritic cell survival and function, M1 macrophage activation 
and T-cell diferentiation and activation [14, 22]. It is also 
involved in central and peripheral tolerance [7, 14, 25] and in 
the development of lymph nodes [21]. Additionally, RANKL 
contributes to regulation of early lymphocyte development 
[14, 21]. With respect to suppression of immune responses, 
RANK–RANKL signalling is required for development 
of medullary thymic epithelial cells, which establish 
T-cell self-tolerance centrally through expression of the 
autoimmune regulator (Aire) gene [14, 65]. Peripherally, 
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RANK–RANKL signalling mediates tolerance and immu-
nosuppression in tissues such as pancreas, small intestine (in 
Peyer’s patches) and skin; defective RANK–RANKL signal-
ling is also implicated in the pathogenesis of autoimmune 
disease in these tissues [7, 14]. RANK–RANKL signalling 
is required for the formation and function of regulatory 
T cells (Tregs) [66, 67]. Speciically, RANKL is involved in 
the generation and activation of potent Tregs in the pancreas 
that are involved in preventing diabetes [66]. RANKL also 
mediates the induction of Tregs in studies of the immune 
environment in skin [67]. Modelling of the immune response 
in mice with colitis has shown that RANKL is expressed by 
Tregs and that blockade of RANK–RANKL signalling can 
impair Treg function and immune suppression [68].
Expression of RANK and RANKL is largely segregated 
among immune cells [7, 25, 69]. RANKL is primarily 
expressed in T cells and is upregulated upon T-cell stimula-
tion, enhancing T-cell proliferation and function. In contrast, 
RANK is expressed in monocytes, macrophages and den-
dritic cells and is induced in T cells and natural killer (NK) 
cells by speciic cytokines [7, 14, 25, 69]. With respect to the 
development of immune responses, RANK–RANKL signal-
ling in dendritic cells enhances their survival and function, 
including their ability to prime and activate T cells, and to 
enhance T-cell memory [70, 71], by inducing expression of 
activating cytokines [7, 14, 25, 72]. Evidence suggests that 
RANK and the co-stimulatory molecule CD40 may act co-
operatively in dendritic cell-mediated activation of T-cell 
responses [14, 71]. Disruption of RANK–RANKL signalling 
can antagonise dendritic cell function and T-cell–mediated 
immune responses [73]. RANK–RANKL signalling in mac-
rophages also enhances their survival and function, includ-
ing antigen presentation [14, 74]. However, the high levels of 
antigens and immunosuppressive factors typically found in 
tumour microenvironments can result in T-cell exhaustion, 
associated with the upregulation of markers, such as immune 
checkpoint proteins; therefore, although dendritic cells may 
initially mediate T-cell diferentiation and activation, exten-
sive inlammation can induce immune suppression [75].
The importance of RANK–RANKL signalling in tumour 
immunology, and in stimulating or suppressing anti-tumour 
immune responses in cancer, is not yet fully understood [7, 
14, 25]. Preclinical studies suggest that RANKL can promote 
the negative selection of tumour-speciic T cells by inducing 
the expression of self-antigens that are shared with tumours 
in the thymus, thereby promoting central tolerance to tumour 
antigens and tumour immune evasion [76]. RANKL inhibi-
tion can reversibly decrease self-antigen expression in the 
thymus and can spare from deletion T cells that target mela-
noma, thus enhancing the anti-tumour immune response 
and improving survival [76]. Furthermore, synergy has 
been observed between the suppression of central tolerance 
in Aire-deicient mice and peripheral immune checkpoint 
inhibition using anti-cytotoxic T-lymphocyte–associated 
antigen-4 (CTLA-4) antibodies with respect to slowing 
tumour growth and improving survival through increasing 
T cells that target melanoma [77]. Co-treatment with anti-
RANKL and anti-CTLA-4 antibodies could not reproduce 
the synergistic efect of Aire-deiciency and anti-CTLA-4 
antibodies on survival, although synergistic improvements 
in survival with co-treatment could be achieved if mice 
were also vaccinated with tumour cells producing granulo-
cyte–macrophage colony-stimulating factor [77].
In addition to establishing central tolerance to tumours 
[7, 14, 76], RANK–RANKL signalling plays an important 
role within tumours where it may contribute to the develop-
ment of a tolerogenic immune microenvironment [25, 60, 
78, 79]. RANK is highly expressed on tumour-associated 
macrophages (TAMs), and RANKL is expressed by tumour-
iniltrating T cells [7, 25, 69]. Tregs inhibit efector T-cell 
activity and can, therefore, play a role in tumour immune 
evasion [80], and as discussed, RANKL plays a crucial role 
in the expansion of Tregs in a variety of situations. Evidence 
suggests that RANK–RANKL signalling in M2 TAMs pro-
duces chemokines that recruit immunosuppressive Tregs to 
the tumour microenvironment [7, 25, 79]. Tregs have been 
shown to produce RANKL, which functions as a chemoat-
tractant for RANK-expressing monocytes [81], suggesting 
that Tregs may perpetuate tumour progression [7, 14, 25, 
60]. Distant metastasis may also be inluenced by RANKL 
expression in tumour-iniltrating T lymphocytes [7, 14, 25]. 
Speciically, Tregs producing RANKL have been implicated 
in the development of lung metastases in a RANK-express-
ing breast cancer mouse model [60]. Although modulation 
of the tumour immune microenvironment could facilitate 
tumour progression, RANKL inhibition in mouse models 
of lung adenocarcinoma that responded to anti-RANKL 
therapy showed only modest changes in the tumour micro-
environment, including non-speciic depletion of tumour 
T cells [38]. In addition to their suggested role in modulat-
ing the tumour immune microenvironment, M2 TAMs have 
also been implicated in angiogenesis and metastasis [25]. 
NK cells play an important role in tumour immunosurveil-
lance [82]; RANKL can stimulate production of NK cell 
inhibitory factors by acute myeloid leukaemia cells, which 
also upregulate RANK expression by NK cells, promoting 
RANK–RANKL signalling that further contributes to NK 
cell inhibition [33].
Therapeutic potential of targeting 
the RANK–RANKL axis in cancer
Denosumab mimics the activity of endogenous OPG in 
binding to RANKL, although it does not inhibit the pro-
apoptotic protein TRAIL [7, 14, 25]. Various trials have 
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Table 1  Cancer clinical trials investigating the repurposing of anti-RANKL therapy
ACTRN Australian New Zealand Clinical Trials Registry, ER oestrogen receptor, NCT National Clinical Trial, PR progesterone receptor, RANKL receptor activator of nuclear factor kappa B 
ligand
Phase Cancer Intervention Primary outcome Status Trial identiier
Proof of concept Breast Denosumab Change in Ki67 expression in 
breast epithelium of BRCA1 
mutation carriers
Active ACTRN12614000694617
1 Breast (stage I–III, at least cT1) Pre-surgical denosumab Pharmacodynamic markers of 
RANKL inhibition
Recruiting NCT02900469
1 Advanced or metastatic cancer 
(relapsed or refractory to  
standard therapy)
Anakinra or denosumab and 
everolimus
Maximum tolerated dose Active but not recruiting NCT01624766
1b/2 Melanoma (unresectable, stage 
III/IV)
Ipilimumab–nivolumab– 
denosumab or  
nivolumab–denosumab
Progression-free survival, grade 
3–4 selected immune-related 
adverse events
Recruiting NCT03161756 (CHARLI)
2 Langerhans cell histiocytosis Denosumab Incidence of patients with active 
disease
Recruiting NCT03270020
2 Breast (stage cT1c to cT4a–d, 
ER negative and PR negative)
Denosumab and neoadjuvant 
therapy
Pathological complete response 
rate
Recruiting NCT02682693 (GeparX)
2 Breast (pre-menopausal, newly 
diagnosed, non-metastatic)
Pre-operative denosumab Geometric mean change in 
tumour Ki67 expression
Closed early due to poor  
recruitment
NCT01864798 (D-BEYOND)
2 Non-small cell lung (stage IV) Denosumab and standard 
therapy
Overall survival Completed NCT01951586
2 Osteosarcoma (recurrent or 
refractory)
Denosumab Disease control rate and  
objective response rate
Recruiting NCT02470091
2 Renal cell carcinoma (unresectable 
or metastatic clear cell)
Denosumab and pembrolizumab Objective response rate Recruiting NCT03280667 (KEYPAD)
2 Giant cell rich tumours of bone Denosumab The proportion of subjects 
who do not require surgery/
who undergo planned versus 
performed surgery during the 
study (salvageable disease); 
disease control and stable pain 
score (unsalvageable disease)
Active EudraCT number 2016-005244-42
3 Breast (stage II/III, high risk for 
recurrence)
Adjuvant denosumab and 
standard neoadjuvant/adjuvant 
therapy
Bone metastasis-free survival Terminated following primary 
analysis
NCT01077154 (D-CARE)
3 Non-small cell lung (stage IV) Denosumab and standard 
therapy
Overall survival Active but not recruiting NCT02129699 (SPLENDOUR)
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recently completed or are in progress, particularly in 
breast and lung carcinoma, that are providing insight into 
the repurposing of denosumab to an anti-cancer therapy 
(Table 1). Anti-RANKL therapy may have the potential to 
help patients with primary bone tumours other than GCTB, 
or who have associated lesions, such as aneurysmal bone 
cysts [83]. Moreover, denosumab is hypothesised to have 
a number of anti-tumourigenic efects including increasing 
bone metastasis-free survival (BMFS), reducing prolifera-
tion and stemness in early tumourigenesis and augmenting 
checkpoint immunotherapy (Fig. 5a, b).
In a phase 3 clinical trial of 1432 patients with castration-
resistant prostate cancer at high risk of bone metastasis, den-
osumab signiicantly increased BMFS, but did not improve 
OS, compared with placebo [84]. A single-arm phase 2a 
study (D-BEYOND), conducted to determine whether 
a short course of neoadjuvant denosumab (two 120 mg 
doses a week apart) can decrease tumour proliferation rates 
(based on Ki67 immunohistochemistry) in newly diagnosed, 
early-stage breast cancer in pre-menopausal women, found 
that a short course of denosumab did not reduce prolifera-
tion rate, but did induce a signiicant increase in tumour-
iniltrating lymphocytes. These data support the hypothesis 
that denosumab may potentiate immunotherapy eicacy 
[85]. ABCSG-18, a phase 3 study using adjuvant denosumab 
(60 mg every 6 months) in patients with oestrogen and/or 
progesterone-positive non-metastatic breast cancer receiv-
ing aromatase inhibitors has demonstrated a 50% reduction 
in fractures alongside a clinically meaningful impact on 
disease-free survival (secondary endpoint) after a median 
follow-up of 72 months (hazard ratio = 0.823, 95% coni-
dence interval 0.69–0.98, p = 0.026) [16]. However, the 
primary analysis of the phase 3 clinical trial D-CARE in 
non-metastatic high-risk early-stage breast cancer patients 
reported that the interventional scheme of denosumab 
(120 mg monthly for 6 months, then every 3 months for 
5 years) failed to demonstrate an improvement over placebo 
with respect to the trial’s unconventional composite primary 
Fig. 5  Targeting of the  
RANK–RANKL pathway may 
improve patient outcomes by  
a reducing self-renewal of cancer 
stem cells and b augmenting 
immunotherapy, tipping the 
balance in favour of the immune 
system. c Concomitant immune 
checkpoint inhibitor and deno-
sumab therapy is associated 
with a higher response rate than 
has been reported for immune 
checkpoint inhibitors alone [17, 
99, 100]a. Red colouring indi-
cates studies of patients with 
melanoma; blue colouring indi-
cates studies of patients with 
NSCLC; square = nivolumab; 
triangle = pembrolizumab; 
circle = atezolizumab, 
hexagon = avelumab; dia-
mond = ICI + denosumab. aAs 
the trials difer in study design 
and methodology, such cross-
trial comparisons should be 
viewed as hypothesis-generating 
only. ICI immune checkpoint 
inhibitor, NSCLC non-small 
lung cell carcinoma, RANK 
receptor activator of nuclear 
factor kappa B, RANKL receptor 
activator of nuclear factor  
kappa B ligand
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endpoint of BMFS [86]. This was deined as the time from 
randomisation to the irst observation of bone metastasis 
or death and, at the primary analysis, death accounted for 
42% of the BMFS endpoint [86], confounding the abil-
ity to observe an efect of denosumab in preventing the 
development of bone metastasis. Moreover, in contrast to 
ABCSG-18, there was a lack of disease-free survival beneit 
in D-CARE [16, 86]. This may however be attributed to the 
heterogeneous high-risk early-stage breast cancer population 
and investigational dosing regimen used in D-CARE [86].
In a retrospective analysis of a phase 3 clinical trial of 
denosumab versus zoledronic acid in the treatment of bone 
metastases from solid tumours, denosumab was associated 
with increased OS in 811 patients with bone metastases 
from any lung cancer [15]. This outcome aligns with evi-
dence from mouse models indicating that RANKL inhibi-
tion impairs the progression of lung adenocarcinomas [38]. 
However, recent prospective data from a phase 2 trial and 
the phase 3 SPLENDOUR trial showed that the addition 
of denosumab to standard irst-line therapy in patients with 
metastatic NSCLC (with or without bone metastases) did 
not improve OS or PFS [87, 88]. Consistent with the above 
retrospective analysis [15], a slight improvement in OS was 
observed in the subgroup of patients with bone metastases 
receiving denosumab in the phase 2 study, but this efect was 
not signiicant [87, 88].
Given the multifactorial roles of the RANK–RANKL 
axis in the immune system, there has been interest in the 
potential of RANKL inhibitors to improve response to 
immune checkpoint inhibitors in the treatment of cancer 
[6, 89]. Inhibitors of immune checkpoint proteins such 
as CTLA-4 and anti-programmed death-1 (PD-1) or its 
ligand have revolutionised treatment for some patients [89]. 
These agents have been approved in several tumour types, 
including melanoma, head and neck squamous carcinoma, 
NSCLC, renal cell and urothelial carcinoma, gastric cancer 
and Hodgkin’s lymphoma [89]. However, their efectiveness 
is limited by variable responses to treatment in individual 
patients; there is a need to improve their activity overall and 
to develop biomarkers that can predict which patients are 
likely to derive beneit from current strategies [89]. Preclini-
cal data and emerging data from real-world practice suggest 
that denosumab and immune checkpoint inhibitors may act 
synergistically [69, 90]. For example, in one case report, 
a patient with melanoma presented 13 months after initial 
diagnosis with an axillary nodal mass and widespread bone 
metastases and demonstrated an unexpected dramatic partial 
response following concomitant treatment with denosumab 
and single-agent ipilimumab (anti-CTLA-4) [90].
Preclinical studies suggest a synergistic efect of anti-
RANKL in combination with anti-CTLA-4 and PD-1 
antibodies, which have demonstrated tumour growth sup-
pression in mouse models of melanoma, prostate and colon 
cancer [91]. In mouse models of melanoma, the addition 
of RANKL inhibition to anti-CTLA-4 antibodies did not 
deplete Tregs, but increased tumour-iniltrating CD4 + and 
CD8 + T cells compared with anti-PD-1 and anti-CTLA-4 
therapy [69, 91]. T-cell effector function (measured by 
cytokine production) was also enhanced in tumours treated 
with both agents compared with tumours treated with either 
single agent [69, 91]. Interestingly, the synergistic efect of 
anti-RANKL and anti-PD-1 antibodies on lung metasta-
sis was dependent upon NK cells, whereas the synergistic 
efect on subcutaneous tumour growth was dependent upon 
T cells [90, 91]. Building on these data, real-world evidence 
using Flatiron Health’s electronic health record database 
from ~ 255 cancer clinics across the US, including patients 
with advanced melanoma or NSCLC, found that a longer 
mean duration of concomitant immune checkpoint inhibitor 
and denosumab therapy was associated with improved over-
all response rate (p = 0.0172 and p < 0.0001 for melanoma 
and NSCLC, respectively) [17]. The response rate associated 
with the combination appears to be higher than reported 
historical response rates to immune checkpoint inhibitors 
alone (Fig. 5c). Additional survival analyses supported the 
association of concomitant therapy and improved survival 
outcomes, primarily in NSCLC (p < 0.0001) [17].
Prospective studies combining denosumab and check-
point inhibitor immunotherapy are in progress. A phase 2 
Australia and New Zealand Urogenital and Prostate Can-
cer Trials Group investigator-sponsored trial (KEYPAD) 
of denosumab and the PD-1 inhibitor pembrolizumab in 
patients with vascular endothelial growth factor receptor 
tyrosine kinase inhibitor-refractory clear cell renal cell car-
cinoma (NCT03280667), and an Australia and New Zea-
land Melanoma Trials Group phase 1b/2 trial (CHARLI) of 
ipilimumab–nivolumab–denosumab and nivolumab–deno-
sumab in patients with unresectable stage III/IV melanoma 
(NCT03161756) are currently recruiting (Table 1). Of note, 
denosumab has an established safety proile in clinical prac-
tice, including when used in combination with novel anti-
cancer agents, with no new detected safety signals to date 
[9, 92].
Discussion and conclusions
Expanding knowledge of biological mechanisms as well as 
bioinformatic and combinatorial screening approaches are 
being used to identify existing agents that may be repur-
posed to beneit people with cancer. Improved knowledge 
relating to the role played by the RANK–RANKL axis in 
the cancer setting has highlighted that agents targeting this 
pathway may be able to modulate diferent stages of tumour 
progression from initiation to metastasis. In this respect, tri-
als are investigating denosumab in diferent cancers with 
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promising results. Such trials also ofer the opportunity to 
identify potentially meaningful clinical synergy with check-
point inhibitor immunotherapies through characterisation 
of the immune efects of denosumab on intratumoural cell 
populations.
A focus for further work will be to establish if there are 
groups of patients likely to derive beneit from denosumab 
as an anti-RANKL agent in cancer in combination with anti-
cancer therapy. For example, the RANKL system is strongly 
inluenced by sex hormones [8, 29], and RANKL activity 
is increased in post-menopausal women lacking oestrogen 
owing to decreased OPG expression [6, 29]. Endogenous 
levels of OPG are lower in BRCA1 mutation carriers, who 
are at greater risk of breast cancer than the general popula-
tion, compared with levels in women without the mutation 
[93]. A trial will assess the efect of denosumab on normal 
breast tissue in these individuals as well as BRCA2 mutation 
carriers and high-risk, non-BRCA carriers [94]. Moreover, 
RANK/RANKL/OPG and LGR4 expression data for pri-
mary tumours, such as renal, breast and lung, may assist in 
identifying patients most likely to beneit from denosumab 
therapy [95].
Overall, given the increased understanding of the pleio-
tropic roles of RANK/RANKL/OPG signalling in tumours 
and immune cells, the repurposing of denosumab, with its 
potential to enhance the eicacy of immuno-oncology drugs, 
could be a cost-efective component of such a combination 
approach for the treatmentof people with cancer.
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